Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis WorseningVlad Ratziu, Juan F. Gallegos‐Orozco, Velimir A. Luketic et al.|Gastroenterology|2016Cited by 1k
Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology CommissionGraham Cooke, Alexandre de Araújo, Isabelle Andrieux‐Meyer et al.|The Lancet. Gastroenterology & hepatology|2019Cited by 539
Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling studyDevin Razavi‐Shearer, Ivane Gamkrelidze, Calvin Q. Pan et al.|The Lancet. Gastroenterology & hepatology|2023Cited by 399
<i>In vivo</i> hepatic endoplasmic reticulum stress in patients with chronic hepatitis CTarik Asselah, Richard Moreau|The Journal of Pathology|2010Cited by 124
Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territoriesDevin Razavi‐Shearer, Nicola Coppola, Hannah Child et al.|Journal of Hepatology|2023Cited by 94